Annual Report

Overview

The report describes Biocon's FY14 launches of ALZUMAb and CANMAB, including affordable treatments for psoriasis and HER2-positive metastatic breast cancer. It records consolidated group revenue growth of 16% to INR 29,332 million. The sustainability section reports 30 tonnes of food waste composted and no recorded fatal accidents during the fiscal year.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2014
Period: 1 April 2013 – 31 March 2014
Language: English
Pages
File size
Restatement: Disclosed

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services